John W. Simon
Chief Executive Officer
John Simon is a co-founder and Director of Acton Pharmaceuticals and also serves as its Chief Executive Officer. Mr. Simon was previously a Vice President at Sepracor where he led the pulmonary/immunology group from 1997 to 2007, resulting in cumulative revenues of $2 billion. John is a co-founder of Forge Therapeutics, a pre-clinical stage company focused on cardiovascular disease. Earlier, John spent seven years at Forest Laboratories and has served as an advisor to health care venture capital funds and early-stage pharmaceutical and drug delivery companies. John has a BA degree from the University of Kentucky.
Daniel L. Kreisler
President and Chief Operating Officer
Daniel Kreisler is co-founder of Acton Pharmaceuticals, serves as its President and Chief Operating Officer and is a member of the Acton Board of Directors. Dan is a specialty pharmaceutical industry veteran with over 25 years of experience. Prior to Acton, Mr. Kreisler was a co-founder of JDS Pharmaceuticals, LLC, a specialty pharmaceutical company formed in 2004 where he held the position of Vice President, Business Development. In 2007, JDS was acquired by Noven Pharmaceuticals, Inc. for $125 million. Prior to co-founding Acton and JDS, Dan was co-founder of Krele Pharmaceuticals. Before that, Dan spent over 16 years at Forest Laboratories where he held positions in marketing management and business development. Dan holds a B.S. degree in Pharmacy from the University of Rhode Island.
Kenneth B. Newman, MD, MBA
Chief Medical Officer and Executive Vice President, Clinical Development and Medical Affairs
Dr. Newman is Acton's Executive Vice President and Chief Medical Officer and is responsible for all clinical research and development and medical affairs. Prior to Acton, Dr. Newman was a Vice President at Boehringer Ingelheim, responsible for all therapeutic categories. Previously, he spent 9 years at Forest Laboratories. Dr. Newman is a well known pulmonary expert and was on faculty at the National Jewish Hospital in Denver, as well as Director of the University of Cincinnati Center for Asthma, Allergies, and Sinus Disorders. He has a B.S. from Duke, M.D. from the University of Texas, and trained at Duke, Johns Hopkins, and the NIH.
Executive Vice President, Pharmaceutical Product Development and Regulatory Affairs
Patrick Noland is Acton's Executive Vice President, Pharmaceutical Product Development and Regulatory Affairs. His responsibilities include all technical and regulatory aspects of drug development including chemistry, formulation, toxicology, and manufacturing. Patrick is a pharmaceutical industry and aerosol formulation veteran with more than 35 years experience spanning the spectrum of drug development. Before joining Acton, he was Vice President of Pharmaceutical Program Development at Analytical Biochemistry Laboratories (ABC), providing CMC and regulatory guidance to industry. Prior to that, Patrick was Senior Director of Quality Control at Sepracor where he contributed to the CMC section of several INDs and four NDAs, two of which were inhalation products that received first-cycle FDA approval. Pat's expertise is internationally recognized and has led to the recent appointment to a five-year term on the USP Panel of Experts (SM4). Pat holds a MS and BS in Chemistry from the University of Missouri-Rolla.
Thomas J. Phair, Jr.
Senior Vice President, Chief Financial Officer
Thomas Phair is Acton's Chief Financial Officer and brings expertise in finance, accounting, and fund raising. Prior to Acton, Tom was Vice President of Finance at Xcellerex, Inc., a supplier of single-use manufacturing technology to pharmaceutical and life sciences companies. From 2006 through 2009, Tom was at Altus Pharmaceuticals where he served in a variety of positions and most recently as Vice President of Finance, Treasurer and Principal Financial Officer. At Altus, Tom was responsible for strategic planning, finance and accounting, legal, facilities and information technology, and led several strategic fund raising initiatives. Prior to Altus, Tom served as Corporate Controller at ArQule, Inc., an early-stage oncology drug development company. In addition, Tom has held financial management positions at PAREXEL, Nashua Corporation and Price Waterhouse. Tom received a BBA in accounting from the University of Massachusetts, Amherst, and is a Certified Public Accountant.
Senior Director, Pharmaceutical Product Development and Quality Affairs
Prior to joining Acton, Bob spent over 20 years at Sepracor (now Sunovian) where, as Director of Developmental Quality Assurance, he gained extensive experience in a virtual setting troubleshooting quality, manufacturing and chemistry issues. There, Bob worked on numerous respiratory drugs including Xopenex Inhalation Solution, Xopenex HFA, Brovana, Alvesco HFA, Omnaris and Omnaris HFA. He made significant contributions to content and strategy for five NDAs for asthma, COPD and allergic rhinitis drugs. He has extensive experience in supporting the quality and commercialization of inhalation products including oral and nasal metered dose inhalers. Bob has an MS in Analytical Chemistry from University of Massachusetts.